195 related articles for article (PubMed ID: 22424119)
1. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
[TBL] [Abstract][Full Text] [Related]
6. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
7. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
Moore AS; Blagg J; Linardopoulos S; Pearson AD
Leukemia; 2010 Apr; 24(4):671-8. PubMed ID: 20147976
[TBL] [Abstract][Full Text] [Related]
11. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
12. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
13. Current assessment of polo-like kinases as anti-tumor drug targets.
Craig SN; Wyatt MD; McInnes C
Expert Opin Drug Discov; 2014 Jul; 9(7):773-89. PubMed ID: 24819909
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.
Zhang Z; Xing X; Guan P; Song S; You G; Xia C; Liu T
Eur J Med Chem; 2021 May; 217():113314. PubMed ID: 33765606
[TBL] [Abstract][Full Text] [Related]
18. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.
Wang NN; Li ZH; Zhao H; Tao YF; Xu LX; Lu J; Cao L; Du XJ; Sun LC; Zhao WL; Xiao PF; Fang F; Su GH; Li YH; Li G; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Ni J; Wang J; Hu SY; Zhu XM; Feng X; Pan J
Int J Mol Sci; 2015 Jan; 16(1):1266-92. PubMed ID: 25574601
[TBL] [Abstract][Full Text] [Related]
20. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]